OP \$540.00 291342

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM448324

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
HESKA CORPORATION		07/27/2017	Corporation: DELAWARE
DIAMOND ANIMAL HEALTH, INC.		07/27/2017	Corporation: IOWA
HESKA IMAGING, LLC		07/27/2017	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	JPMORGAN CHASE BANK, N.A.
Street Address:	Commercial Banking, 1125 17th Street, 3rd Floor
City:	Denver
State/Country:	COLORADO
Postal Code:	80202
Entity Type:	National Banking Association: UNITED STATES

PROPERTY NUMBERS Total: 21

Registration Number: 37 Registration Number: 35)13428 '53400	IMMUCHECK
Registration Number: 35	753400	EDD
		ERD
Registration Number: 35	09683	HEMATRUE
3	38197	HESKAVIEW INTEGRATED SOFTWARE
Registration Number: 24	94527	HESKA
Registration Number: 26	555214	HESKA
Registration Number: 21	77633	HESKA
Registration Number: 29)48416	HESKA
Registration Number: 24	74543	HESKA
Registration Number: 33	336031	HESKA
Registration Number: 26	28459	HESKA
Registration Number: 26	523862	HESKA
Registration Number: 25	30646	ALLERCEPT
Registration Number: 25	09741	SOLO STEP
Registration Number: 24	54228	VET/SENSOR
Registration Number: 39	008910	VITALPATH

TRADEMARK

REEL: 006188 FRAME: 0635

900426110

Property Type	Number	Word Mark
Registration Number:	4318224	ELEMENT DC
Registration Number:	4851518	ELEMENT I
Registration Number:	4550666	ELEMENT POC
Registration Number:	4849883	ELEMENT HT5
Registration Number:	1917148	DIAMOND

CORRESPONDENCE DATA

Fax Number: 8446706009

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 313-223-3098

Email: nzemgulis@dickinsonwright.com

Correspondent Name: M. Katherine VanderVeen
Address Line 1: 500 Woodward Avenue

Address Line 2: Suite 4000

Address Line 4: Detroit, MICHIGAN 48226

ATTORNEY DOCKET NUMBER:	7-7705
NAME OF SUBMITTER:	M. Katherine Vanderveen
SIGNATURE:	/M. Katherine VanderVeen/
DATE SIGNED:	10/24/2017

Total Attachments: 18

source=Heska_Patent_and_Trademark_Security_Agreement#page1.tif source=Heska_Patent_and_Trademark_Security_Agreement#page2.tif source=Heska Patent and Trademark Security Agreement#page3.tif source=Heska Patent and Trademark Security Agreement#page4.tif source=Heska Patent and Trademark Security Agreement#page5.tif source=Heska_Patent_and_Trademark_Security_Agreement#page6.tif source=Heska Patent and Trademark Security Agreement#page7.tif source=Heska Patent and Trademark Security Agreement#page8.tif source=Heska_Patent_and_Trademark_Security Agreement#page9.tif source=Heska_Patent_and_Trademark_Security_Agreement#page10.tif source=Heska_Patent_and_Trademark_Security_Agreement#page11.tif source=Heska_Patent_and_Trademark_Security_Agreement#page12.tif source=Heska Patent and Trademark Security Agreement#page13.tif source=Heska_Patent_and_Trademark_Security_Agreement#page14.tif source=Heska_Patent_and_Trademark_Security_Agreement#page15.tif source=Heska Patent and Trademark Security Agreement#page16.tif source=Heska Patent and Trademark Security Agreement#page17.tif source=Heska_Patent_and_Trademark_Security_Agreement#page18.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

THIS PATENT AND TRADEMARK SECURITY AGREEMENT (this "Agreement") is entered into as of July 27, 2017 by Heska Corporation, a Delaware corporation, Diamond Animal Health, Inc., an Iowa corporation, and Heska Imaging, LLC, a Delaware limited liability company (each a "Grantor", and collectively, the "Grantors"), in favor of JPMorgan Chase Bank, N.A., in its capacity as administrative agent (the "Administrative Agent") for the lenders party to the Credit Agreement referred to below.

Recitals

- A. The Grantors, the lenders party thereto, and the Administrative Agent are entering into a Credit Agreement dated as the date hereof (as it may be amended, restated, supplemented or otherwise modified from time to time, the "*Credit Agreement*").
- B. In connection with the Credit Agreement, the Grantors are entering into that certain Pledge and Security Agreement dated as of the date hereof (as amended or modified from time to time, the "Security Agreement") with the Administrative Agent. All capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Security Agreement.
- C. Pursuant to the terms of the Security Agreement, each Grantor pledged, assigned, and granted to the Administrative Agent, on behalf of and for the ratable benefit of the Lenders, a first-priority security interest (subject to Permitted Liens (as defined in the Credit Agreement)) in substantially all of the assets of such Grantor, including all right, title, and interest of such Grantor in, to, and under all now owned and hereafter acquired Patents, patent applications, patent licenses, Trademarks, trademark applications, and trademark licenses, and all products and proceeds thereof, to secure the prompt and complete payment and performance of the Secured Obligations as (defined in the Credit Agreement).
- D. Pursuant to the terms of the Security Agreement, the Grantors are required to execute and deliver to the Administrative Agent, for the ratable benefit of the Lenders, this Agreement.

Agreement

In consideration of the recitals set forth above and the mutual agreements contained herein and in the Credit Agreement and other Loan Documents, each Grantor hereby grants to the Administrative Agent, for the benefit of the Lenders, to secure the Secured Obligations, a continuing security interest in all of such Grantor's right, title, and interest in, to, and under the following, whether now owned by or owing to, or hereafter acquired by or arising in favor of such Grantor (including any trade name or derivations thereof):

(1) each trademark and trademark application, including without limitation, each trademark and trademark application referred to in <u>Schedule 1</u> attached hereto, together with any reissues, continuations, or extensions thereof and all goodwill associated therewith;

- (2) each trademark license, including without limitation, each trademark license listed on Schedule 1 attached hereto, together with all goodwill associated therewith;
- (3) all products and proceeds of the foregoing, including without limitation, any claim by the Grantor against third parties for past, present, or future infringement of any trademark, including without limitation, any trademark referred to in Schedule 1 attached hereto, any trademark issued pursuant to a trademark application referred to in Schedule 1, and any trademark licensed under any trademark license listed on Schedule 1 attached hereto (items 1 through 3 being herein collectively referred to as the "Trademark Collateral");
- each patent and patent application, including without limitation, each patent referred to in <u>Schedule 2</u> attached hereto, together with any reissues, continuations, or extensions thereof and all goodwill associated therewith;
- (5) each patent license, including without limitation, each patent license listed on Schedule 2 attached hereto, together with all goodwill associated therewith;
- (6) all products and proceeds of the foregoing, including without limitation, any claim by the Grantor against third parties for past, present, or future infringement of any patent, including without limitation, any patent referred to in <u>Schedule 2</u> attached hereto, any patent issued pursuant to a patent application, and any patent licensed under any patent license listed on <u>Schedule 2</u> attached hereto (items 4 through 6 being herein collectively referred to as the "<u>Patent Collateral</u>").

The security interests granted to the Administrative Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Administrative Agent pursuant to the Security Agreement; provided, however, that nothing in this Agreement shall expand, limit, or otherwise modify the security interests granted in the Security Agreement. Each Grantor acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademark Collateral and the Patent Collateral made and granted hereby are more fully set forth in the Credit Agreement and the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

This Agreement shall be governed by, and construed in accordance with, the internal laws (and not the law of conflicts) of the State of New York, but giving effect to federal laws applicable to national banks.

[Signature page follows]

IN WITNESS WHEREOF, the Grantors have executed this Agreement as of the date first set forth above.

GRANTORS:

HESKA CORPORATION DIAMOND ANIMAL HEALTH, INC. HESKA IMAGING, LLC

Name: John McMahon

Title: Chief Financial Officer of each of the above, on

behalf of each of the above

JPMORGAN CHASE BANK, N.A., as Administrative Agent

By: Mouis Popous Name: Monica Popowczak

Title: Authorized Officer

$\underline{\textbf{SCHEDULE 1}}$

to

PATENT AND TRADEMARK SECURITY AGREEMENT

TRADEMARKS

See attached.

TRADEMARK APPLICATIONS

See attached.

Z010-41-CH-1	2010-41-CT	3819 41 CU-K	0000 A4 00 0	3818 4 7 4	2618-A1-CA	2618-41-BR-2	2618-41-BR	2618-41-AU-2	2618-41-AU-1	2618-41-AU	2515-41-5	25 8-4 -4	2010-41-3	7-14-0107	2010-41-1	3010 41 4	3840 44	2618-143-CA	, id.	3548 443	2618-142-CA	2818-142	2618-136-2	2010-13U-JP-1	2018-130-CA	2518-130-AU	2618-123-1W-1	2618-123-TW	2618-123-TH	2618-123-KR	12518-123-HK	2618-122-JP	2618-117-NO	2516-117-CIM	7018-117-CH	MI O-401-07	2010-105	NUMBER	HESKA FILE
Duellazime	DUBLISZIJAC	Callada	Cariava	Constant	Canada	Bravil	Brazil	Australia	Australia	Australia	USA	USA	USA	NOA	NOA	500		Canada	Š	1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Canada	1000	4211	Japan	Canada	Australia	Tawan	Taiwan	Thailand	South Korea	Hong Kong	Japan	Norway	European Union	Switzerland	European Union	USA		COUNTRY
HESKA	HESKA	HESKA	THORA		THOUS	CCOC.	HESKA	HISKA	HESKA	HESKA	HESKA	HESKA	HESKA	HESKA	HESKA	HEOKA	ARE	HESKAVIEW INTEGRATED	SOFTWARE		THE WATER TO SE	LEW LE	CON	ERD -HEALTHSCREEN w/		E.R.DHEALTHSCREEN	TRI-HEART	TRI-HEART	TRI-HEART	TRI-HEART	TRI-HEART	HESKA in Katakana	H-SCREEN	E-SCREEN	E-SCREEN	IMMUCHECK	MMUCHECK		TRADEMARK
446 156	444 805	TMA574,232	TMA545,654	(NIASSB, 841	088208028	000007810	0100000	80/1675	732620	702979	3,336,031	2,474,543	2,948,416	2,177,633	2,655,214	2,494,527		TMA746550	3,538,197	1 NIA /4 1000	3,500,583	3,733,400	2 322 622	5141567	TMA651,278	953376	1418709	1233979	TM269052	40-0685701	300580554	4624176	212129	001933282	493 504	002885154	2,913,428	NUMBER	REGISTRATION
11/17/1997	9/22/1997	1/22/2003	5/28/2001	3/6/2002	6/17/2014	0002//1/01	2002/002	0000/3/8	2/0/1008	5/29/1997	11/13/2007	7/31/2001	5/10/2005	7/28/1938	12/3/2002	10/2/2001		8/31/2009	11/25/2008	6002/6/6	9/30/2008	2/23/2010		6/13/2008	10/24/2005	6/28/2004	7/16/2010	11/1/2006	10/16/2007	11/15/2006	7/13/2006	11/22/2002	12/6/2001	7/25/2003	7/1/2002	12/1/2003	12/21/2004	DATE	REGISTRATION
03226/1997	01478/1996	1,096,586	842405	805330	830902880	819225568	07,00,80	020201	723830	702979	78/531 627	75/980 370	76/144,611	75/977,369	75/420,172	75/034,381	1,000,114	1 380 774	77/273,909	1,385,154	77/243,946	78/981,276		2006-100052	1177640	953376	98047611	95006936	619166	40-2006-0011110	300580554	2001-112667	2000 13104	001933282	252520.1	002685154	75/912,501	NUMBER	APPLICATION
4/24/1997	3/4/1996	3/20/2001	4/16/1997	2/26/1996	1/11/2011	5/10/1996	1.002/87/8	1661/01/4	Caching In	2/22/4000	MUCUS 1761	1/20/1998	10/10/2000	12/19/1995	1/20/1998	12/19/1995	0007/07/13	4/35/3000	9/7/2007	3/4/2008	8/1/2007	2/23/2010		10/27/2006	5/12/2003	5/12/2003	10/28/2009	2/15/2006	3/38/2/06	3/3/2008	2/14/2008	12/18/2001	10/26/2000	10/27/2000	10/27/2000	4/3/2002	2/8/2000	DATE	ONIE
40	05 10	10, 31	40	8	ô	GS.	i	42	CO	200	On co	10	3:	83	05	05 42	S	**************************************	09	OS.	05, 10	44		Ö	ö	10	9,6	0,50	On Co	3 8	2	05 10 49	100	15.		05 42 44	42	,	CLASSES
		REGISTERFD	REGISTERED	REGISTERED	REGISTERED	REGISTERED	REGISTERED	KEGIS ERED	REGISTERED	NEGIO I EXEU		7397TS1038	REGISTERED	Cadalssicad	REGISTERED	REGISTERED	REGISTERED		REGISTERED	REGISTERED	REGISTERED	REGISTERED		REGISTERED	REGISTERED			PEGISTERED	700000000000000000000000000000000000000			BEGINTERED				ת חור	REGISTERED	~~~	SHLVAS

SKA 1088630 SKA 1088630 SKA 2018580 SKA 2018580 SKA 218815 SKA 35055 SKA 20200488AA 4838918 4215403 4875403 4215403 SKA 40-0714321 SKA 187509 SKA 197881 SKA 197881 SKA 197882 SKA 197862 SKA 197862 SKA 197862 SKA 198027682 SKA 198027662 SKA 1980277 SKA 19802782 SKA 19802782	10/20/1008	Ĵ	274385 3/20/199
		10/30/1996	۱
		11/11/1999	
SIGN SIGN SIGN SIGN SIGN SIGN SIGN SIGN	8	11/27/1998	
SIGN SIGN SIGN SIGN SIGN SIGN SIGN SIGN	: }	1/25/2003	
		12/4/2000	12/4/2000 200106759AA
	- 3	11/4/1998	
Sign Sign Sign Sign Sign Sign Sign Sign	- 3	9/21/2002	9/21/2002 20010/5/5551 4/11/2001
Sign Sign Sign Sign Sign Sign Sign Sign	- 3	9/21/2002	~~30
SIGN SIGN SIGN SIGN SIGN SIGN SIGN SIGN	- }	10/22/1997	10/22/1997 2677/1997
SIGN SIGN SIGN SIGN SIGN	- 3	1/22/2003	1/22/2003 1098585
SIGN SIGN	- 8	4/3/2002	4/3/2002 840115
SIGN SIGN		12/14/1999	12/14/1999 819905496
SIGN SIGN		5/8/2002	90674
ESIGN		1/30/1998	73037
	3	9/24/2002	9/24/2002 76/221,281
	{ :	10/1/2002	10/1/2002 75/189.883
NUMBER 1088630 SKA 1088630 SKA 1906801 SKA 2015580 SKA 2015580 SKA 35055 SKA 35055 SKA 4838918 SKA 4838918 SKA 1280578 SKA 1280578 SKA 1280578 SKA 197881 SKA 708642 SKA 756027662 SKA 1976027662 SKA 1976027662 SKA 1976027662		1/31/1998	1/31/1998 (86)19642
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 2015680 SKA 35055 SKA 35055 SKA 402700488AA SKA 402714321 SKA 1250578 SKA 1250578 SKA 197867 SKA 708642 SKA 7086424 SKA 199705350H SKA 199705350H	8	4/16/1997	4/16/1997 (85)9563
NUMBEN SKA 1068630 SKA 1906801 SKA 2015580 SKA 2015580 SKA 35055 SKA 3638618 SKA 4638618 SKA 40-0714321 SKA 1280578 SKA 1280578 SKA 1280578 SKA 70-0714321 SKA 1280578 SKA 1280578 SKA 1280578 SKA 1280578 SKA 197861 SKA 187509 SKA 1196027662 SKA 1196027662		10/22/2007	10/22/2007 619165
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 2018815 SKA 35085 SKA 35085 SKA 4638918 SKA 40-0714321 SKA 197881		5/8/1997	5/8/1997 T97/05350H
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 2015580 SKA 36056 SKA 36056 SKA 20200488AA A638918 SKA 4215403 SKA 1280578 SKA 197881 SKA 197881 SKA 197881 SKA 197881 SKA 1978642		12/19/1995	12/19/1995 T96/02766Z
NUMBER SKA 1068630 SKA 1908801 SKA 2015580 SKA 2015580 SKA 35055 SKA 35055 SKA 20200488AA SKA 4215403 SKA 40-0714321 SKA 197881 SKA 197881 SKA 197881 SKA 197881	1	2/25/2004	2/25/2004 708642
NUMBER 1088630 3KA 1906801 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 521740 SKA 4002004884A SKA 4215403 SKA 40-0714321 SKA 1280578 SKA 197881	į	7/30/1998	7/30/1998 259206
NUMBER 1088630 SKA 1098630 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 521740 SKA 400200489AA SKA 400714321 SKA 1260578 SKA 1260578		12/18/1997	12/18/1997 97.3116
NUMBER 1088630 SKA 1906801 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 521740 SKA 200200489AA SKA 4638918 SKA 4638918 SKA 40-0714321 SKA 1260578		6/9/1999	6/9/1999 96 1270
SKA 1088630 SKA 1088630 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 521740 SKA 200200488AA SKA 4638918 SKA 4638918 SKA 40-0714321	1	1/16/2012	1/36/2012 1146865
SKA 1088630 SKA 1088630 SKA 1908631 SKA 2015580 SKA 218815 SKA 35055 SKA 350740 SKA 4638918 SKA 4638918	1	6/21/2007	6/21/2007 40-2006-0011109
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 350740 SKA 202700486AA SKA 4638918	1	11/27/1998	
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055 SKA 521740 SKA 202300488AA	3	1/25/2003	1/25/2003 8-32003
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 213815 SKA 35055 SKA 521740	- 3	12/4/2000	12/4/2000 200200488AA
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 218815 SKA 35055	- 3	12/14/1998	12/14/1998 521740
NUMBER SKA 1068630 SKA 1906801 SKA 2015580 SKA 216815		9/6/1989	9/6/1999
NUMBEK SKA 1906801 SKA 2015580		7/8/1999	7/8/1999 98056943
NUMBER 1088630 SKA 1906801		9/21/2002	9/21/2002 2001056271
SKA 1088630		8/7/2002	8/7/2002 2001056270
NIMBER		8/7/1997	8/7/1997 960038820
		HATE	DATE NUMBER
TRADENIARK REGISTRATION RE-	22	CISTRATION	GISTRATION APPLICATION

	3/48/400%	74.401 087		1917148	DIAMOND AND DESIGN	C.S.	70001#US0
-	10/15/2015	1268876		1029762	ELEMENT HTS	New Zealand	2618-215-NZ
	10/15/2015	1268876		1268876	ELEMENT HTS		2618-215-NO
***	10/16/2015	1268876		1268876	ELEMENT HIS	ž	2618-215-C1M
	10/15/2015	1268876		1268876	ELEMENT HTS		2618-215-CH
05. 10	10/15/2015	1268876	1/28/2016	1728208	ELEMENT HTS	Australia	2618-215-AU
0	2/27/2015	86/548,170		A,849,883	ELEMENTHTS		2618-215
	9/12/2013	86/062,771		4,550,666	ELEMENT POC		2518-213
	2/2/2012	85/531,712		A,851,518	ELEMENT		502-8182
٠	12/21/2011	35/501,345		4,318,224	ELEMENT DC		2018-207
10	3/16/2010	1,478,308		841,936	VIIALPAIH		2618-170-CA
	9/18/2009	77/830223		3.908.910	VITALPATH		2618-170
	12/21/1998	75/612,052		2,454,228	VET/SENSOR	1	26.68-86
05	3/14/2000	2000-24733		4454194	SOLO STEP w/ Katakana		2618-76-JP-1
***************************************	9/29/1999	11-88921		4406804	SOLO STEP	į.	2010-75-JF
3	5/7/2002	1136071		TWA636,108	SOLO STEP		2018-76-3-UA
		76/169,305		2,509,741	SOLO STEP		2018-76-3
S		1180788	6/10/2013	1190788	>CmzCmv		VQ 10-00-XX
05,44	8/10/2013	1190788			ALLERCEPT		8010-03-8G
4		1190788	8/14/2015	1190788	ALLERCEPT	1	7518-63-XC
8	6/10/2013	1190788	8/10/2013	1190788	ALLERCEPT		2618-63-PL
3	6/10/2013	1180788	6/10/2013	1190788	ALTEROMOT		2618-63-NZ
8	8/31/2001	2001 10495	12/27/2001	212.574	ALLERCEPT		2618-63-NO
8	6/10/2013	1190788	6/15/2015	1546775	ALLEROEPT		2618-63-MX
8	6/10/2013	1190788	8/10/2013	1190788	ALLERCEPT	1	2618-63-39
3	8/29/1997	620138	11/18/1999	620138	ALLERCEPT	13	2618-63-C1M
G.	8/10/2013	1190788	6/10/2013	1190788	ALERCEPT		2618-63-CN
S	8/30/2001	8557/2001	7/16/2002	501047	ALLERCEPT		2618-63-CH
08 44	6/14/2013	1631209			ALLERCEPT	Canada	2618-63-CA
3	6/10/2013	1190788	6/10/2013	1190788	ALLERCEPT		2618-63-AU
å	7/16/1997	75/980,372	1/15/2002	2,530,646	ALLERCEPT		2618-63-2
0	7/16/1997	75/325,290	8/27/2002	2,612,937	ALLERCEPT	USA	2618-63
	4/1/1997	5.953/87	89811843	S-10.293	HESKA AND DESIGN	Venezuela	2618-51-VE-1
05	4/1/1997	5.952/97	9,87,1999	P-213.369	HESKA AND DESIGN	Venezuela	2818-51-VE
***************************************	4/11/1997	(86)17444	1/1/1998	097209	HESKA AND DESIGN	awan	2618-51-TW-1
Carle and to Name of	DATE	NOMBER	NAIX.	ZENBER			NUMBER
~, ~, io.			アー・ディング アー・デンス	WASHING WALLES	E MANSELES ANN	(C C C S S X X X	ANALONS A RELAC

SCHEDULE 2

to

PATENT AND TRADEMARK SECURITY AGREEMENT

PATENTS

See attached.

PATENT APPLICATIONS

None.

DETROIT 7-7705 1429701v1

U.S. Issued Patents owned solely by Heska Corporation (as of June 12, 2017)

TELEVISION OF MENDS I ABLEST !	***************************************	**************************************				
MESKA PILE WINES	book book book book	APPLICATION	FILE DATE	U.S. PATENT	IUSSIE	- 3:
2618-17-C2-PUS-1	Ectoparasite Saliva Proteins	10/271,344	10/14/2002	7 166 693 B2	1/23/2007	
2618-17-C5-PUS-1	Ectoparasite Saliva Proteins and Apparatus to Collect Such Proteins	09/004,730	1/8/1998	6,485,968 B1	11/26/2002	DEM 88 FI
2618-25-C1-2	Flea Protease Proteins, Nucleic Acid Molecules and Uses Thereof	08/485,443	6/7/1995	6,146,870	11/14/2000	\$
2618-25-C6	Flea Protease Proteins, Nucleic Acid Molecules and Uses Thereof	09/032,215	2/27/1998	6,204,010 B1	3/20/2001	ISSUED
2618-43-1-1	Anti-Parasitic Helminth Macrophage Migration Inhibitory Factor Antibodies and Uses Thereof	09/774,377	1/30/2001	6,455,039 B2	9/24/2002	ISSUED
2618-45-2	Antiparasitic Helminth Larval Thiol Specific Antioxidant Antibodies and Uses Thereof	09/477,510	1/4/2000	6,489,448 B1	12/3/2002	ISSUED
	Canine COX-2 Nucleic Acid Molecules and Uses Thereof	09/919,060	7/31/2001	6,638,744 B2	10/28/2003	ISSUED
	Canine COX-2 Proteins and Uses Thereof	12/352,511	1/12/2009	7,666,641	2/23/2010	ISSUFD
AL-2-C3	Dermatophagoides Nucleic Acid Molecules, Proteins and Uses Thereof	09/292,225	4/15/1999	6,455,686 B1	9/24/2002	ISSUED
AL-2-C3-1	Novel Dermatophagoides Proteins and Uses Thereof	10/218,743	8/13/2002	7,256,263 B2	8/14/2007	ISSUED
AL-2-C4	Novel Dermatophagoides Proteins and Uses Thereof	09/662,293	9/14/2000	7,128,921 B1	10/31/2006	ISSUED
+	Novel Dermatophagoides Proteins and Uses Thereof	11/506,444	8/18/2006	7,891,187	9/15/2009	ISSUED
	Feline Immunoglobulin E Molecules and Compositions Thereof	09/479,614	1/7/2000	6,573,372 B2	6/3/2003	ISSUED
	Feline Immunoglobulin E Molecules and Related Methods	10/409,772	4/7/2003	7,183,386 B2	2/27/2007	ISSUED
AL-5	Canine Low Affinity IgE Receptor (CD23) Nucleic Acid Molecules and Uses Thereof	09/535,521	3/24/2000	6,410,714 B1	6/25/2002	ISSUED

U.S. Issued Patents owned solely by Heska Corporation (as of June 12, 2017)

US-1	Compositions and Methods Related to Canine IgG and Canine IL-13 Receptor Canine IL-13 Receptor Alpha-1 Subunit Nucleic Acid Molecules Detection of Anti-FcEpsilonR Autoantibodies in Asthmatics Delivery Method for Recombinant Raccoon Poxvirus Cationic Lipid-Mediated Enhancement of Nucleic Acid Immunization of Cats Cationic Lipid-Mediated Enhancement of Nucleic Acid Immunization of Cats Methods for Detecting Early Renal Disease in Animals	APPLICATION NUMBER 09/828,995 10/753,159 10/753,159 09/018,798 10/864,903 11/866,558 11/866,558	FILE DATE 4/9/2001 1/7/2004 1/2/5/1997 2/4/1998 6/9/2004 10/3/2007 3/28/2007	U.S. PATENT NUMBER 6,703,360 B2 7,378,275 B2 6,165,799 6,165,799 8,029,776 B2 7,172,873 B2	ISSUE BATE 3/9/2004 5/27/2008 12/26/2000 8/22/2000 1/1/2007
DI-13-C2-1 Methods Animals	Methods of Detecting Early Renal Disease in Animals	111/627,784	1/26/2007	7,935,495 B2	5/3/2011
	Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules and Uses Thereof	09/015,734	1/29/1998	6,057,127	5/2/2000
	Equine Fc Epsilon Receptor Alpha Chain Proteins and Uses Thereof	09/515,311	2/29/2000	6,582,701 B1	6/24/2003
DI-4-2 Anti-Ec Antibo	Anti-Equine Fc Epsilon Receptor Alpha Chain Antibodies and Method to Detect IgE	10/434,817	5/8/2003	6,887,672 B2	5/3/2005
DI-4-3 Equine	Equine Fc Epsilon Receptor Alpha Chain	11/086.903	3/21/2005	7 77% 99% ₩7	6/8/78/3
DV-6-C1 Haemo	Haemobartonella PCR Methods and Materials	09/398,577	9/17/1999	6.518.620 R1	2/11/2/11/3
D1.7-C1 PCR M	PCR Methods and Materials	09/398,179	9/17/1999	6 308 072 B1	1000/0/01
	Infranasal Delivery System	09/408 584	0/70/1000	6 308 774 51	1987/6/01
CI-PUS	Intranasal Delivery System	10/0800,504	5000C/LC/E	7 764 877 81	8/4/2002
	Forms Intersected Political Control	10/007,229	2007/17/6	1,204,822 81	4/1//2007

U.S. Issued Patents owned solely by Heska Corporation (as of June 12, 2017)

	Flea Head, Nerve Cord, Hindgut and	Flea GABA Receptor Subunit Nucleic Acid Molecules	Flea Peritrophin Nucleic Acid Molecules	Flea Allantoinase Proteins and Uses Thereof	Flea Chitinase Nucleic Acid Molecules and	Flea Ultraspiracle Nucleic Acid Molecules	Flea Ultraspiracle Nucleic Acid Molecules and Uses Thereof	Flea Ecdysone and Ultraspiracle Nucleic Acid Molecules, Proteins and Uses Thereof	Anti-Flea Epoxide Hydrolase Antibodies and Uses Thereof	Flea Epoxide Hydrolase Proteins and Uses Thereof	Flea Epoxide Hydrolase Nucleic Acid Molecules, Proteins and Uses Thereof	Novel Flea Epoxide Hydrolase Nucleic Acid Molecules, Proteins and Uses Thereof	Serine Protease Inhibitor Nucleic Acid Molecules and Uses Thereof	Flea Octopamine Receptor Nucleic Acid Molecules, Proteins and Uses Thereof		L.E. K.KJK.KJ
09/387,809	11/565,729	12/352,535	11/778,533	f 10/180,165	09/545,814	11/697,551			d 09/634,530	09/471,528	09/182,816		09/005,352	12/200,456	APPLICATION	
9/1/1999	12/1/2006	1/12/2009	7/16/2007	6/26/2002	4/7/2000	4/6/2007	5/27/2004	11/5/1999	8/8/2000	12/27/1999	10/29/1998	12/12/1997	1/9/1998	8/28/2008	198 9	
6,203,825 B1	8,088,903 B2	8,268,976	7,662,622 B2	6,905,682 B2	6,416,977 BI	7,667,019	7,208,589 B2	6,489,140 B1	6,290,958 B1	6,153,397	6,143,542		σ.	7,932,371 в2	U.S. PATENT	***
3/20/2001 4/2/2002	1/3/2012	9/18/2012	2/16/2010	6/14/2005	7/9/2002	2/23/2010	4/24/2007	12/3/2002	9/18/2001	11/28/2000	111/7/2000	3/14/2000	11/12/2002	4/26/2011	ISSUE	
ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED RAD	ISSUED 6	SILVIS	

U.S. Issued Patents owned solely by Heska Corporation (as of June 12, 2017)

Presentation (100 pt 100 pt 10						
HESKA FILE NUMBER	(00) (00) (00) (00) (00)	APPLICATION	FILE DATE	U.S. PATENT	EUSSI E	STATUS
77777		NUMBER		NUMBER	A	R
T &	Parasitic Helminth Cuticlin Nucleic Acid Molecules and Uses Thereof	09/323,427	6/1/1999	6,24 8 ,329 B1	6/19/2001	ISSUED MA
HW-8-1	Parasitic Helminth Cuticlin Nucleic Acid Molecules and Uses Thereof	09/812,642	3/20/2001	6,368,600 B1	4/9/2002	RADE
HW-9	Parasitic Helminth DIAg2 Proteins, Nucleic Acid Molecules, and Uses Thereof	09/361,434	7/27/1999	6,136,963	10/24/2000	ISSUED TF
HW-9-1	Parasitic Helminth DIAg2 Proteins and Uses Thereof	09/635,025	8/4/2000	6,392,017 B1	5/21/2002	ISSUED
IM-1-C1-PUS-1	Canine and Feline B7-2 Proteins, Compositions and Uses Thereof	10/790,396	3/1/2004	7,053,181 B2	5/30/2006	ISSUED
IM-2-C1-1	Canine IL-4 Nucleic Acid Molecules and Uses Thereof	10/218,654	8/13/2002	7,078,506 B2	7/18/2006	ISSUED
IM-2-C1-2	Feline Granulocyte Macrophage Colony	11/486,995	7/14/2006	7,780,959 B2	8/24/2010	ISSIED
IM-2-C1-3	Feline Granulocyte Macrophage Colony Stimulating Factor Nucleic Acid Molecules	12/819,964	6/21/2010	8,263,559	9/11/2012	ISSUED
IM-2-C1-C1-1	Canine IL-5 Nucleic Acid Molecules	10/787,382	2/24/2004	7,183,080 B2	2/27/2007	ISSUED
IM-2-C1-C1-2	Canine IL-5 Proteins and Fragments Thereof	11/561,562	11/20/2006	7,427,661 B2	9/23/2008	ISSUED
IM-2-C1-R	Canine IL-4 Immunoregulatory Proteins and Uses Thereof	10/916,286	8/11/2004	RE39,614 E (Reissue)	05/08/2007	ISSUED
IM-2-C2-1	Canine IL-13 Nucleic Acid Molecules and Uses Thereof	10/262,439	9/30/2002	7,026,139 B2	4/11/2006	ISSUED
IM-2-C2-R	Canine IL-13 Immunoregulatory Proteins and Uses Thereof	10/918,292	8/13/2004	RE40,374 E	06/10/2008	ISSUED
IM-5-1	Feline IL-12 Single Chain Nucleic Acid Molecules	10/821,670	4/9/2004	7,205,143 B2	4/17/2007	ISSUED
IM-5-3	Feline IL-18 Nucleic Acid Molecules	12/128,440	5/28/2008	7,928,197 B2	4/19/2011	ISSUED
IN-1-C5	Electrode for Evaluating Cardiac Functions Via Esophagus	09/513,737	2/22/2000	6,438,400 B1	8/20/2002	ISSUED
				***************************************	********************************	**************************************

U.S. Issued Patents owned solely by Heska Corporation (as of June 12, 2017)

TITLE APPLICATION	2905	U.S. PATENT	BSSI	
		NUMBER		
	12/18/1998	6.514.694 B2	2/4/2003	CHISSI
			1 to	1000010
		7.052.899 B2	5/30/2006	CELISSI
	:		: : : : : :	
	Methods for the Detection of Encysted 09/216,393 Parasites 09/321,856 Methods for the Detection of Encysted 10/321,856	APPLICATION F NUMBER 09/216,393 10/321,856	7 6 5	APPLICATION FILE DATE U.S. PATENT ISSUE NUMBER NUMBER DATE 09/216,393 12/18/1998 6,514,694 B2 2/4/2003 10/321,856 12/17/2002 7,052,899 B2 5/30/2006

	DI-4-DK	DI-4-DE	D[-4-CH	DI-4-BE	DI-2-PCA	Dt-1-pJP	DI-1-PEP	DI-1-PCA	DI-1-PAU-1	DI-1-IT	DE	DI-1-GB	DI-1-FR	DI-1-ES	DI-I-DK	DI-1-DE	DI-I-CH	DI-13-C2-PEP	AL-Z-C3-PAU	MARKIN	HESKA FILE
	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Theroof	Novel Feline FC Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	Method to Detect IgE	Methods of Detecting Early Renal Disease in Animals	Novel Dermatophagoides Nucleic Acid Molecules, Proteins and Uses Thereof													
O	99905532.0	99905532.0	99905532.0	99905532.0	2,273,855	10-526731	97949625.4	2,270,868	57951/01	97949625.4	97949625.4	97949625.4	97949625.4	97949625.4	97949625.4	97949625.4	97949625.4	02733963.9	36521/99	NUMBER	APPLICATION
	1/26/1999	1/26/1999	1/26/1999	1/26/1999	12/16/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	11/24/1997	3/28/2002	4/16/1999	DATE	PNCIE
	1051491	National no. to be assigned	1051491	1051491	2,273,855	3993245	943097	2,270,868	769954	0943097	0943097	0943097	0943097	0943097	0943097	69723860.1- 08	0943097	02733963.9	762249	MARMON	GRANTED
	7/14/2010	7/14/2010	7/14/2010	7/14/2010	5/27/2003	8/3/2007	7/30/2003	1/24/2006	5/27/2004	7/30/2003	7/30/2003	7/30/2003	7/30/2003	7/30/2003	7/30/2003	7/30/2003	7/30/2003	12/16/2009	10/2/2003	DATE	IUSSI
	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANIED	GRANTED	GRANTED	GRANTED	GRANTED	GRANIED	GRANTED	GRANTED D	EMAI	SULVIS V

CRANIED	5/30/2006	2,386,110	9/29/2000	2,386,110	Intranasal Delivery System	EQ-2-C1-PCA
GRANIED	12/14/2000	00001744007	+002//////	7007267000	Intranasal Delivery System	EQ-2-C1-PAU-2
	10/14/2004	22281CVVIIIC	10/7/2004	20014218666	Intranasal Delivery System	EQ-2-C1-PAU-1
(10/00/00/	77777	0/20/2000	77376/00	Intranasal Delivery System	EQ-2-C1-PAU
GRANTED	7/14/2010	99905532.0	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-SE
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	LR-4-P]
GRANTED	7/14/2010	1051491	1/26/1999	99905532	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-PEP
GRANTED	5/24/2011	2,319,310	1/28/1999	2,319,310	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DJ-4-PCA
GRANTED	8/1/2002	746218	1/28/1999	25674/99	Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-PAU
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-NL
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-11
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-IE
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-GB
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-FR
GRANTED	7/14/2010	1051491	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DI-4-FI
GRANTED	7/14/2010	2348971	1/26/1999	99905532.0	Novel Equine Fc Epsilon Receptor Alpha Chain Nucleic Acid Molecules, Proteins and Uses Thereof	DJ-4-ES
SEATE	DATE	GRANIED PATENT NUMBER	BATE	APPLICATION NUMBER	P 8 8 9 8 . 8 8 .	NUMBER NUMBER

	r C-3-C1-NL	F0-3-C1-IT	FO-3-C1-GB	FO-3-Cl-FR	FO-3-CI-ES	FO-3-C1-DE	FO3-CI-AT	FC-6-CZ-PEP	F.C-0-C1-F.F.F.	EQ-2-C1-PCA-2	EQ-2-CI-PCA-1	HESKA FILE NUMBER
တ	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Flea Peritrophin Nucleic Acid Molecules, Protoins and Uses Thereof	Fica Head, Nerve Cord, Hindgut and Malpighian Tubule Nucleic Acid Molecules, Proteins and Uses Thereof	Intranasal Delivery System	Intranasal Delivery System	ELIE
	99968209.9	99968209.9	99968209.9	99968209.9	99968209.9	99968209.9	99968209.9	1977740.8	918540.6	2,640,663	2,541,848	APPLICATION
	9/1/1999	9/1/1999	9/1/1999	9/1/1999	9/1/1999	9/1/1999	9/1/1999	10/11/2001	4/7/2000	9/25/2008	9/29/2000	FILING
	01109457	01109457	01109457	01109457	01109457	01109457	E 243943	1328662	1169343	2,640,663	2,541,848	GRANIED
***************************************	7/2/2003	7/2/2003	7/2/2003	7/2/2003	7/2/2003	7/2/2003	7/2/2003	9/8/2010	5/24/2006	9/13/2011	12/2/2008	BSUE
***************************************	GRANTED	GRANTED	1	-	GRANTED C	STATUS EMARK						

	FO-3-CI-SE	1 C 1 C 1 T 1 L 1	EU 3 CI BEB	FO-3-CL-PCA		FO-3-CI-PAU	NUMBER	HESKAFILE
Carbohydrate Metabolism	Method to Manufacture a Composition to Protect an Obligate Carnivore From a Disease of Abnormal	Obligate Carnivore From a Disease of Abnormal Carbohydrate Metabolism	Metabolism	Composition to Protect an Ol rom a Disease of Abnormal C	Metabolism	Method and Composition to Protect an Obligate		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	99968209.9	999709.9		2,342,861		60252/99	NUMBER	APPLICATION
	9/1/1999	9/1/1999		9/1/1999		9/1/1999	DATE	FILING
	01109457	1109457		2,342,861		769669	PATENT	GRANTED
	7/2/2003	7/2/2003		6/9/2009		5/13/2004	DATE	RUSSI
	GRANTED	GRANTED		GRANTED	TR/	GRANTED \D	≣MA	STATUS RK

REEL: 006188 FRAME: 0654

RECORDED: 10/24/2017

O